Visual Field and Graves Ophthalmopathy
Whether primary or secondary to thyroid disease, Graves\u27 ophthalmopathy is surprising by its evolution despite correct treatment. Transformation to acute mode may occur very quickly.
Sabine Defoort-Dhellemmes; Jean-Philippe Woillez; Virginie Rufin
core
Multiparametric MRI quantitative metrics for grading and staging graves' ophthalmopathy. [PDF]
Wu S +6 more
europepmc +1 more source
Epigenetic Modulation of Thyroid-Stimulating Hormone Receptor Expression in Orbital Fibroblasts From Graves' Ophthalmopathy: Target for Treatment. [PDF]
Chompoowong R +9 more
europepmc +1 more source
Correction: Extraocular muscle index as a novel indicator of inflammatory condition in graves' ophthalmopathy patients. [PDF]
Wu F +5 more
europepmc +1 more source
Euthyroid Graves' Ophthalmopathy With Negative Antibodies (EGONA): A Comprehensive Case-Based Review. [PDF]
Bonny M +6 more
europepmc +1 more source
New-Onset Graves' Ophthalmopathy After Treatment with Pembrolizumab: A Case Report and a Review of the Literature. [PDF]
Pan M, Zhou X, Wu Y.
europepmc +1 more source
Clinical value of dual-energy CT parameters combined with morphological features in predicting graves' ophthalmopathy. [PDF]
Ma Z +7 more
europepmc +1 more source
Immunopathogenesis of Graves\u27 Ophthalmopathy
Clinical Background. Course of Ophthalmopathy. This may occur at any time in relation to thyrotoxicosis and myoxedema. May improve, worsen, or not change with thyrotoxicosis management, and its uncertain relationship to medical, radioactive iodine, and ...
Robert C. Sergott
core
Emerging therapeutic approaches in graves' ophthalmopathy: an update on pharmacological interventions. [PDF]
Wang L, Chen L.
europepmc +1 more source
Effect of orbital fat decompression on eyelid contour according to midpupil lid distance in graves' ophthalmopathy. [PDF]
Wang YW, Huang WL, Liao SL, Wei YH.
europepmc +1 more source

